Daily FNArena News - Australia

As Telix Pharmaceuticals turns the page on 2025, its annus horribilis, analysts remain optimistic around a potential valuation re-rating

Overviews in raw numbers and calculations that might assist investors with assessing trends and currents that might not be apparent from daily volatility and movements

2025 saw a sharp reversal in momentum for ASX-listed equities. Are there any lessons for 2026?

Overviews in raw numbers and calculations that might assist investors with assessing trends and currents that might not be apparent from daily volatility and movements

Overviews in raw numbers and calculations that might assist investors with assessing trends and currents that might not be apparent from daily volatility and movements

Overviews in raw numbers and calculations that might assist investors with assessing trends and currents that might not be apparent from daily volatility and movements

Australia’s general insurers face a new mandatory cost –the “AI Governance Tax”– forcing billions in defensive spending to meet FAR compliance and avoid algorithmic bias penalties before they can capture AI efficiency gains

Overviews in raw numbers and calculations that might assist investors with assessing trends and currents that might not be apparent from daily volatility and movements

Flight Centre has re-rated on competitor woes but following a new acquisition and an improving backdrop analysts see further re-rating potential

This story features regulatory enforcement priorities affecting private credit providers, superannuation funds, asset managers, banks, and general insurers across both listed and unlisted sectors